Number of involved anatomic areas as a risk predictor in pediatric Hodgkin's lymphoma: A retrospective study

Jornal de Pediatria

Volumn 85, Issue 3, 2009, Pages 236-242

  Morais, Adriana ^a   Barros, Mário Henrique M ^b   Hassan, Rocio ^b   Morais, Vera L L ^a   Muniz, Maria Tereza Cartaxo ^a,c,d  

^a Hospital Universitario Oswaldo Cruz   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c Oncohematology Pediatric Center   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Childhood; Hodgkin's lymphoma; Involved anatomic areas; Late effects; Risk groups

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGE; ARTICLE; AXILLARY LYMPH NODE; BLOOD CELL COUNT; BONE DISEASE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CERVICAL LYMPH NODE; CHILD; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; ENDOCRINE DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; HEARING DISORDER; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INGUINAL LYMPH NODE; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MESENTERY LYMPH NODE; METASTASIS; NEPHROTOXICITY; OVERALL SURVIVAL; PATIENT SELECTION; REMISSION; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TREATMENT RESPONSE; WALDEYER RING;

ADOLESCENT; AGE FACTORS; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; ENDOCRINE SYSTEM DISEASES; EPIDEMIOLOGIC METHODS; FEMALE; HEART DISEASES; HODGKIN DISEASE; HUMANS; MALE; PROGNOSIS; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 67049088365     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1891     Document Type: Article

References (31)

1. Hodgson DC. Hodgkin Lymphoma: the follow-up of long-term survivors. Hematol Oncol Clin North Am. 2008;22:233-244
2. Thomson AB, Wallace WH. Treatment of paediatric Hodgkin\'s disease. A balance of risks. Eur J Cancer. 2002;38:468-477 (Pubitemid 34185385)
3. Barros MH, Morais VL, Soares SM, Leite EP, Ramos SV. Late effects in Brazil: experience of the Cured Evaluation Program. Med Pediatr Oncol. 2003;41:361 (Abstract).
4. Diehl V, Klimm B, Re D. Hodgkin lymphoma: a curable disease: what comes next? Eur J Haematol Suppl. 2005;(66):6-13.
5. Schwartz CL. Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl. 2005;(66):55-62. (Pubitemid 40873979)
6. Hodgson DC, Hudson MM, Constine LS. Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007;17:230-242 (Pubitemid 46970823)
7. Montalbán C, García JF, Abraira V, González-Camacho L, Morente MM, Bello JL, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004;22:1664-1673 (Pubitemid 41079805)
8. Specht L, Nordentoft AM, Cold S, Clausen NT, Nissen NI. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988;61:1719-1727
9. Hasenclever, D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol. 2002;13 Suppl 1:75-78
10. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, et al. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol. 2001;67:279-288 (Pubitemid 34135440)
11. Zander T, Wiedenmann S, Wolf J. Prognostic factors in Hodgkin's lymphoma. Ann Oncol. 2002;13 Suppl 1:67-74.
12. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood. 1997;90:2429-2436 (Pubitemid 27392727)
13. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20:1278-1287 (Pubitemid 34177434)
14. Sánchez-Aguilera A, Montalbán C, de la Cueva P, Sánchez-Verde L, Morente MM,García-Cosío M, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108:662-668 (Pubitemid 44061368)
15. Engel M, Essop MF, Close P, Hartley P, Pallesen G, Sinclair-Smith C. Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases. J Clin Pathol. 2000;53:182-186 (Pubitemid 30163599)
16. Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, et al. Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. J Clin Oncol. 2005;23:4048-4056 (Pubitemid 46211309)
17. Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood. 2005;106:2444-2451 (Pubitemid 41510819)
18. Jaffe ES, Harris NL, Stein H, et Vardiman JW, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
19. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin\'s Disease Staging Classification. Cancer Res. 1971;31:1860-1861
20. Hudson M, Onciu M, Donaldson S. Hodgkin lymphoma. In: Pizzo P, Poplack D, editors. Principles and practice of pediatric oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2006. p.: 695-721.
21. Viani GA, Castilho MS, Novaes PE, Antonelli CG, Ferrigno R, Pellizzon CA, et al. Chemotherapy followed by low dose radiotherapy in childhood Hodgkin\'s disease: retrospective analysis of results and prognostic factors. Radiat Oncol. 2006;1:38.
22. Cox, DR. Regression Models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
23. Kaplan E, Meier P. Non Parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481
24. Oberlin O, Leverger G, Pacquement H, Raquin MA, Chompret A, Habrand JL, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602-1608 (Pubitemid 23057990)
25. Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DALHD- 90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol. 1999;17:3736-3744
26. Smith RS, Chen Q, Hudson MM, Link MP, Kun L, Weinstein H, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol. 2003;21:2026-2033 (Pubitemid 46606393)
27. Oguz A, Karadeniz C, Okur FV, Citak EC, Pinarli FG, Bora H, et al. Prognostic factors and treatment outcome in childhood Hodgkin disease. Pediatr Blood Cancer. 2005;45:670-675 (Pubitemid 41279358)
28. Gobbi PG, Ghirardelli ML, Solcia M, Di Giulio G, Merli F, Tavecchia L, et al. Image-aided estimate of tumour burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol. 2001;19:1388-1394 (Pubitemid 32202545)
29. Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol. 1988;41:359-367 (Pubitemid 19003752)
30. Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden. Eur J Haematol. 1988;41:80-87 (Pubitemid 18197624)
31. Specht L, Nissen NI. Hodgkin's disease and age. Eur J Haematol. 1989;43;127-135 (Pubitemid 19246052)